EBITDA: Income before interest, taxes, depreciation and amortization.
Relay Therapeutics, Inc. (RLAY) had EBITDA of $-80.74M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-74.15M |
|
-- |
|
-- |
|
$80.39M |
|
$-80.39M |
|
$6.24M |
|
$-74.15M |
|
$-74.15M |
|
$-74.15M |
|
$-74.15M |
|
$-74.15M |
|
$-74.15M |
|
$-80.39M |
|
|
EBITDA |
$-80.74M |
172.39M |
|
172.39M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$624.01M |
|
$2.36M |
|
$45.99M |
|
$670.00M |
|
$32.60M |
|
-- |
|
$29.69M |
|
$62.29M |
|
$607.71M |
|
$607.71M |
|
$607.71M |
|
172.63M |
|
| Cash Flow Statement Financials | |
$-190.59M |
|
$157.34M |
|
$0.67M |
|
$126.41M |
|
$93.82M |
|
$-32.58M |
|
$49.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-191.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.20% |
|
-12.20% |
|
-11.07% |
|
-12.20% |
|
$3.52 |
|
$-1.11 |
|
$-1.11 |
|